TruScreen trims annual sales forecast on delayed product launch

TruScreen trims annual sales forecast on delayed product launch
Paul McBeth
By Paul McBeth Oct. 2 (BusinessDesk) - TruScreen, the NZAX-listed cervical cancer test developer, says annual sales won't be as big as previously forecast due to a delay in the commercial launch of an upgraded screening device. The hold-up in rolling out its TruScreen Ultra product by several months reduced sales, which were about $300,000 in the six months ended Sept. 30, and that will flow into annual revenue, which will be below the $10.6 million forecast in the company's listing disclosure document, it said in a statement. "Revenue...